Dynavax Technologies Co. (NASDAQ:DVAX) Position Lessened by Royce & Associates LP

Royce & Associates LP reduced its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 5.4% in the third quarter, Holdings Channel.com reports. The institutional investor owned 374,119 shares of the biopharmaceutical company’s stock after selling 21,563 shares during the period. Royce & Associates LP’s holdings in Dynavax Technologies were worth $4,168,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Dynavax Technologies by 1.4% during the first quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock valued at $116,682,000 after acquiring an additional 126,458 shares during the period. Kynam Capital Management LP grew its position in Dynavax Technologies by 180.0% in the 1st quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company’s stock worth $52,616,000 after purchasing an additional 2,725,397 shares during the last quarter. Renaissance Technologies LLC increased its stake in shares of Dynavax Technologies by 2.2% in the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock valued at $27,830,000 after purchasing an additional 53,600 shares during the period. Great Point Partners LLC raised its holdings in shares of Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after buying an additional 1,109,080 shares during the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Dynavax Technologies during the second quarter worth approximately $17,615,000. 96.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. The Goldman Sachs Group cut their target price on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research note on Thursday, August 8th. HC Wainwright restated a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Stock Down 4.3 %

DVAX stock opened at $11.69 on Tuesday. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market cap of $1.54 billion, a PE ratio of 89.93 and a beta of 1.34. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $15.01. The firm has a 50 day simple moving average of $11.39 and a 200 day simple moving average of $11.31.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.